Trial reportLeukemia2023
Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial.
Open access · hybridAbstract readClinical Trial, Phase II
In one paragraph
Trial report in Leukemia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- AXL Inhibitors in Oncology Clinical Trials: A Review.Journal of immunotherapy and precision oncology · 2026Review
- [Role of Receptor Tyrosine Kinase AXL in Cancer Targeted Therapy Drug Resistance].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Review
- Cancer-associated fibroblast-derived GAS6 increases resistance to chemotherapy through AXL/STAT3/ABCG1 in gastric cancer.British journal of cancer · 2026Article
- Paratope mapping of tilvestamab, an anti-AXL function-blocking antibody, using high-throughput bacterial expression of secreted scFv-osmY fusion proteins.Bioscience reports · 2025Article
- Targeted Therapies Modulating Mesenchymal-Epithelial Transition-Linked Oncogenic Signaling in the Tumor Microenvironment: Comparative Profiling of Capmatinib, Bemcentinib, and Galunisertib.Journal of clinical medicine · 2025Review
- The Receptor Tyrosine Kinase Axl in (Advanced) Gastric Cancer-From Pathophysiology to Therapeutic Impact.Medicina (Kaunas, Lithuania) · 2025Review
- Untangling the loops ofLeukemia & lymphoma · 2025Review
- PD-1 interactome in osteosarcoma: identification of a novel PD-1/AXL interaction conserved between humans and dogs.Cell communication and signaling : CCS · 2024Article
- AXL as immune regulator and therapeutic target in Acute Myeloid Leukemia: from current progress to novel strategies.Experimental hematology & oncology · 2024Review
- Therapeutic advances of targeting receptor tyrosine kinases in cancer.Signal transduction and targeted therapy · 2024Review
- AXL inhibition suppresses early allograft monocyte-to-macrophage differentiation and prolongs allograft survival.JCI insight · 2024Article
- An Overview of Targeted Therapies in Acute Myeloid Leukemia.HemaSphere · 2023Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 12 institutions in 3 countries.
A S KubaschDepartment of Hematology, Hemostaseology, Cellular Therapy and Infectious Diseases, Leipzig University Hospital, Leipzig, Germany.ORCID 0000-0002-0747-4941
P PeterlinThe European Myelodysplastic Neoplasms Cooperative Group (EMSCO), Leipzig, Germany.
T CluzeauThe European Myelodysplastic Neoplasms Cooperative Group (EMSCO), Leipzig, Germany.ORCID 0000-0002-6745-1127
K S GötzeGerman MDS Study Group (D-MDS), Leipzig, Germany.
K SockelGerman MDS Study Group (D-MDS), Leipzig, Germany.
R TeipelDepartment of Internal Medicine I, University Hospital Carl Gustav Carus Dresden, TU Dresden, Dresden, Germany.
M JentzschDepartment of Hematology, Hemostaseology, Cellular Therapy and Infectious Diseases, Leipzig University Hospital, Leipzig, Germany.ORCID 0000-0002-2270-0804
H AttalahGroupe Francophone des Myélodysplasies, Paris, France.
M SebertGroupe Francophone des Myélodysplasies, Paris, France.
F ChermatGroupe Francophone des Myélodysplasies, Paris, France.
S GloaguenGerman MDS Study Group (D-MDS), Leipzig, Germany.
M PuttrichGWT-TUD GmbH, Dresden, Germany.
M CrossDepartment of Hematology, Hemostaseology, Cellular Therapy and Infectious Diseases, Leipzig University Hospital, Leipzig, Germany.ORCID 0000-0002-8815-7621
M SchneiderDepartment of Hematology, Hemostaseology, Cellular Therapy and Infectious Diseases, Leipzig University Hospital, Leipzig, Germany.ORCID 0000-0001-9022-5470
S KayserInstitute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, German Red Cross Blood Service Baden-Württemberg-Hessen, Mannheim, Germany.
D SchippDS-Statistics, Rosenthal-Bielatal, Germany.
A GiagounidisGerman MDS Study Group (D-MDS), Leipzig, Germany.
I Tirado-GonzalezGeorg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany.
A DescotGeorg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany.
A van de LoosdrechtThe European Myelodysplastic Neoplasms Cooperative Group (EMSCO), Leipzig, Germany.ORCID 0000-0001-8311-983X
A WeigertDepartment of Hematology, Hemostaseology, Cellular Therapy and Infectious Diseases, Leipzig University Hospital, Leipzig, Germany.
K H MetzelerDepartment of Hematology, Hemostaseology, Cellular Therapy and Infectious Diseases, Leipzig University Hospital, Leipzig, Germany.ORCID 0000-0003-3920-7490
P FenauxThe European Myelodysplastic Neoplasms Cooperative Group (EMSCO), Leipzig, Germany.
H Medyouf *Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany.
U Platzbecker *Department of Hematology, Hemostaseology, Cellular Therapy and Infectious Diseases, Leipzig University Hospital, Leipzig, Germany. uwe.platzbecker@medizin.uni-leipzig.de.ORCID 0000-0003-1863-3239
L Ades *The European Myelodysplastic Neoplasms Cooperative Group (EMSCO), Leipzig, Germany.ORCID 0000-0002-9020-8766
University Hospital Leipzig · DEUniversité Paris Cité · FRGeorg Speyer Haus · DEGerman Cancer Research Center · DEGroupe Francophone des Myélodysplasies · FRUniversity Hospital Carl Gustav Carus · DEAmsterdam University Medical Centers · NLCentre Hospitalier Universitaire de Nantes · FRCentre Hospitalier Universitaire de Nice · FRGWT-TUD (Germany) · DEMarien Hospital Düsseldorf · DETUM Klinikum · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Leukemia, Myeloid, AcuteMyelodysplastic SyndromesBenzocycloheptenesHumansTriazolesbemcentinibBenzocycloheptenesTriazoles
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.